Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation
Conditions
Interventions
Intervention1: Ipratropium Bromide delivery via pMDI through Easy2Neb mask during NIV therapy.: Ipratropium Bromide (20mcg) via pMDI, 2 puffs 6 hourly for first 24 hours while on NIV therapy.
Control
Sponsors
Pt. B. D. Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged >40 years. 2. Clinically suspected patients in AECOPD. 3. Patients of COPD in type 2 respiratory failure and pH between 7.25-7.35.
Exclusion criteria
Exclusion criteria: 1. Any obstructive or restrictive respiratory disease other than COPD. 2. Hemodynamically unstable, defined as systolic blood pressure 3. Patients in need of emergency intubation. 4. Arterial pH 5. Patients in altered sensorium or Glasgow Coma Scale (GCS) less than 12. 6. Patients with facial deformity, trauma or surgery where proper oronasal mask seal cannot be ensured. 7. Patients with hypersensitivity to Levosalbutamol, coronary artery disease (CAD), tachyarrhythmias, and diabetic ketoacidosis (DKA).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the level of Ipratropium Bromide in blood post aerosol therapy using pMDI versus jet nebulizer via face mask during NIV therapy.Timepoint: 30 minutes, 1 hour & 6 hours after aerosol therapy (prior to the next dose) in both arms. | — |
Secondary
| Measure | Time frame |
|---|---|
| pH, pO2 & pCO2 will be measuredTimepoint: Before & after 2 hours of aerosol therapy in both arms.;Respiratory rate (RR), heart rate (HR) & oxygen saturation by pulse oximeter (SpO2) will be measuredTimepoint: 30 minutes, 1 hour & 6 hours after aerosol therapy (prior to the next dose) in both arms. | — |
Countries
India
Contacts
Public ContactVishal Raj
Pt. B. D. Sharma PGIMS Rohtak
Outcome results
None listed